Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs
BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery.
- BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery.
- Ginkgo has acquired Reverie's infrastructure and software for training large-scale AI foundation models and four of Reverie's key AI team members will join Ginkgo.
- The acquisition is intended to strengthen Ginkgo's AI/ML-driven discovery services offering and to accelerate Ginkgo's work to build next-generation biological foundation models .
- Reverie's generative AI platform for chemistry will also be added into Ginkgo's capabilities to support small molecule programs.